Amorepacific increases participation in COSRX and becomes main share owner

Amorepacific increases participation in COSRX and becomes main share owner

Amorepacific, who already owned 38.4% of COSRX shares, has announced the acquisition of the 288,000 remaining shares held by COSRX’s largest shareholder and related parties for 755.1 billion won. Following this transaction, Amorepacific is expected to own 93.2% of COSRX shares. As a consequence, the brand will be integrated as a subsidiary of the South Korean group.

Founded in 2013, COSRX is a hypoallergenic skincare brand designed for sensitive skin. Centered around the ’Advanced Snail’ line and ’The RX’ line, it has experienced rapid growth, establishing itself as a rising global skincare player. According to Amorepacific, the company has shown an average annual sales growth rate of over 60% in the past three years, reporting 204.4 billion won in 2022. This year, in the first half alone, it has achieved 190.2 billion won in sales and 71.7 billion won in operating profit, continuing its sharp growth trend.

Moreover, the brand has expanded to around 140 countries, including North America, Southeast Asia, Europe, and Japan, with overseas sales accounting for over 90% of its total. Since it entered Amazon in 2018, essential products such as the ’Advanced Snail 96 Mucin Power Essence’ have topped the Beauty & Personal Care category, particularly distinguishing itself in the North American market. Additionally, COSRX has been recognized as a brand with exceptional digital communication capabilities, evidenced by its TikTok challenge launched in 2022, which saw over 2.1 billion cumulative hashtag views.

After the equity investment in 2021, both companies co-developed and launched products such as ’The Vitamin C 23 Serum’ and ’The Retinol 0.1 Cream’ from COSRX’s next-generation core line, The RX, achieving success overseas. In this vein, Amorepacific plans to accelerate its global expansion through multifaceted collaboration with COSRX, which boasts strong global competitiveness.


No votes yet.
Please wait...

Leave a Reply

Your email address will not be published. Required fields are marked *